Antiviral Drugs Market To Surpass USD 74.7 Billion By 2027 At A CAGR Of 3.7%
The report analyzes and forecasts the Antiviral Drugs Market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2022 to 2030. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global Antiviral Drugs Market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the Antiviral Drugs Market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of Antiviral Drugs Market for the base year 2020 and the forecast between 2021 and 2028. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Download Sample Report Copy From Here:https://www.acumenresearchandconsulting.com/request-sample/2534
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding. Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
Market Players as below:
Players operating in the global antiviral drugs market are Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, and Dr. Reddy’s Laboratories Ltd.
The major market segments of Antiviral Drugs Market are as below:
Market By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
Market By Type
Branded
Generic
Market By Application
HIV
Hepatitis
Herpes
Influenza
Others
Ask Query Here: richard@acumenresearchandconsulting.com or sales@acumenresearchandconsulting.com
Table Of Contents:
CHAPTER 1. Industry Overview of Antiviral Drugs
1.1. Definition and Scope
1.1.1. Definition of Antiviral Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Antiviral Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Antiviral Drugs Market By Type
1.2.3. Antiviral Drugs Market By Drug Class
1.2.4. Antiviral Drugs Market By Application
1.2.5. Antiviral Drugs Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Antiviral Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Antiviral Drugs Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Proportion of Manufacturing Cost Structure
3.8.1.1. Raw Material
3.8.1.2. Labor Cost
3.8.1.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Antiviral Drugs Major Manufacturers in 2019
CHAPTER 5. Antiviral Drugs Market By Type
5.1. Introduction
5.2. Antiviral Drugs Revenue By Type
5.2.1. Antiviral Drugs Revenue (US$ Mn) and Forecast, By Type, 2016-2027
5.2.2. Branded
5.2.2.1. Branded Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Generic
5.2.3.1. Generic Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Antiviral Drugs Market Revenue By Drug Class
6.1. Introduction
6.2. Antiviral Drugs Revenue (US$ Mn) By Drug Class
6.2.1. Antiviral Drugs Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
6.2.2. DNA Polymerase Inhibitors
6.2.2.1. DNA Polymerase Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. Reverse Transcriptase Inhibitors
6.2.3.1. Reverse Transcriptase Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.4. Protease Inhibitors
6.2.4.1. Protease Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.5. Neuraminidase Inhibitors
6.2.5.1. Neuraminidase Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.6. Others
6.2.6.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. Antiviral Drugs Market By Application
7.1. Introduction
7.2. Antiviral Drugs Revenue (US$ Mn) By Application
7.2.1. Antiviral Drugs Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
7.2.2. HIV
7.2.2.1. HIV Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.3. Hepatitis
7.2.3.1. Hepatitis Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.4. Herpes
7.2.4.1. Herpes Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.5. Influenza
7.2.5.1. Influenza Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.6. Others
7.2.6.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 8. North America Antiviral Drugs Market By Country
8.1. North America Antiviral Drugs Overview
8.2. U.S.
8.2.1. U.S. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.2.2. U.S. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.2.3. U.S. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
8.3. Canada
8.3.1. Canada Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.3.2. Canada Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.3.3. Canada Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
8.4. North America PEST Analysis
CHAPTER 9. Europe Antiviral Drugs Market By Country
9.1. Europe Antiviral Drugs Market Overview
9.2. U.K.
9.2.1. U.K. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.2.2. U.K. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.2.3. U.K. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.3. Germany
9.3.1. Germany Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.3.2. Germany Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.3.3. Germany Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.4. France
9.4.1. France Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.4.2. France Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.4.3. France Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.5. Spain
9.5.1. Spain Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.5.2. Spain Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.5.3. Spain Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.6. Rest of Europe
9.6.1. Rest of Europe Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.6.2. Rest of Europe Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.6.3. Rest of Europe Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Antiviral Drugs Market By Country
10.1. Asia Pacific Antiviral Drugs Market Overview
10.2. China
10.2.1. China Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
10.2.2. China Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.2.3. China Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
10.3. Japan
10.3.1. Japan Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
10.3.2. Japan Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.3.3. Japan Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
10.4. India
10.4.1. India Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
10.4.2. India Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.4.3. India Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
10.5. Australia
10.5.1. Australia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
10.5.2. Australia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.5.3. Australia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
10.6. South Korea
10.6.1. South Korea Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
10.6.2. South Korea Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.6.3. South Korea Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
10.7.2. Rest of Asia-Pacific Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.7.3. Rest of Asia-Pacific Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Antiviral Drugs Market By Country
11.1. Latin America Antiviral Drugs Market Overview
11.2. Brazil
11.2.1. Brazil Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
11.2.2. Brazil Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
11.2.3. Brazil Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
11.3. Mexico
11.3.1. Mexico Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
11.3.2. Mexico Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
11.3.3. Mexico Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
11.4. Rest of Latin America
11.4.1. Rest of Latin America Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
11.4.2. Rest of Latin America Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Antiviral Drugs Market By Country
12.1. Middle East & Africa Antiviral Drugs Market Overview
12.2. Saudi Arabia
12.2.1. Saudi Arabia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
12.2.2. Saudi Arabia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
12.2.3. Saudi Arabia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
12.3. UAE
12.3.1. UAE Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
12.3.2. UAE Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
12.3.3. UAE Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
12.4.2. Rest of Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
12.4.3. Rest of Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. PLAYER ANALYSIS OF ANTIVIRAL DRUGS
13.1. Antiviral Drugs Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Antiviral Drugs Market
CHAPTER 14. COMPANY PROFILE
14.1. Gilead Sciences
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Mn), 2019
14.1.3.2. Gilead Sciences 2019 Antiviral Drugs Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Manufacturing Plant Footprint Analysis
14.2. F. Hoffmann-La Roche AG
14.3. GlaxoSmithKline plc
14.4. AbbVie
14.5. Merck & Co., Inc.
14.6. Johnson & Johnson Services, Inc.
14.7. Bristol-Myers Squibb Company
14.8. Cipla Inc.
14.9. Aurobindo Pharma
14.10. Dr. Reddy’s Laboratories Ltd.
14.11. Others
To Get Premium Report Full Copy in Form of Single user or Multiple user@https://www.acumenresearchandconsulting.com/buy-now/0/2534
About Us:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
